{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:15:29Z","timestamp":1790748929018,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T00:00:00Z","timestamp":1586822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PT13\/0010\/0007"],"award-info":[{"award-number":["PT13\/0010\/0007"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00443","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T08:28:09Z","timestamp":1586852889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap"],"prefix":"10.3389","volume":"11","author":[{"given":"Miguel","family":"Piris-Villaespesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Alvarez-Twose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp. Hematol."},{"key":"B2","unstructured":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature6895068963\n            Alvarez-TwoseI.\n            MatitoA.\n            MorgadoJ. M.\n            Mu\u00f1ozL.--.\n            Jara-AcevedoM.\n            Garc\u00eda-MonteroA.\n          Oncotarget.82017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.leukres.2018.12.010","article-title":"Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis","volume":"77","author":"Broderick","year":"2019","journal-title":"Leuk Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of KIT: Link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412","volume":"38","author":"de Melo Campos","year":"2014","journal-title":"Leuk Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia."},{"key":"B10","article-title":"Avapritinib (blu285), a selective kit inhibitor, is associated with high response rate and tolerable safety profile in advanced systemic mastocytosis (advsm): results of a phase 1 study","volume-title":"EHA Annual Meeting, 2018. Abstract PF612","author":"Deininger","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl. J. Med."},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT","volume-title":"PLoS ONE","author":"Dubreuil","year":"2009"},{"key":"B13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"B14","first-page":"17","article-title":"PKC412\u2013a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabrro","year":"2000","journal-title":"Anticancer Drug Des."},{"key":"B15","first-page":"1115","article-title":"Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant 11","volume":"1","author":"Frost","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Garc\u00eda-Montero","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica."},{"key":"B21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00432-015-1988-0","article-title":"Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study","volume":"141","author":"Hochhaus","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","article-title":"Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications","volume":"28","author":"Jara-Acevedo","year":"2015","journal-title":"Mod Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia."},{"key":"B27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"B28","first-page":"1410","article-title":"Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells","volume":"146","author":"Kirshenbaum","year":"1991","journal-title":"J. Immunol. Baltim Md 1950"},{"key":"B29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am. J. Hematol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002068","article-title":"Mutation D816V Alters the Internal Structure and Dynamics of c-KIT Receptor Cytoplasmic Region: Implications for Dimerization and Activation Mechanisms","volume":"7","author":"Laine","year":"2011","journal-title":"Verkhivker GM editor. PloS Comput. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am. J. Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"B34","unstructured":"Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis11951205\n            L\u00fcbkeJ.\n            NaumannN.\n            KlugerS.\n            SchwaabJ.\n            MetzgerothG.\n            EvansE.\n          Leukemia.332019"},{"key":"B35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.bjc.6603331","article-title":"The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study","volume":"95","author":"Millward","year":"2006","journal-title":"Br. J. Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib: Mast cell leukemia with KIT mutation","volume":"86","author":"Mital","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/annonc\/mdh052","article-title":"Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer","volume":"15","author":"Monnerat","year":"2004","journal-title":"Ann. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2018","journal-title":"Blood Adv."},{"key":"B39","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1385\/IR:34:2:97","article-title":"Development, Migration, and Survival of Mast Cells","volume":"34","author":"Okayama","year":"2006","journal-title":"Immunol. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: The role of KIT mutations","volume":"138","author":"Orfao","year":"2007","journal-title":"Br. J. Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am. J. Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"B44","unstructured":"Pooled Survival Analysis Of Midostaurin Clinical Study Data (D2201 + A2213) In Patients With Advanced Systemic Mastocytosis (Advsm) Compared With Historical Controls\n            ReiterA\n            Kluin-NelemansH. C.\n            GeorgeT.\n            AkinC.\n            DeAngeloD. J.\n            HermineO.\n          EHA annual meeting 20172017"},{"key":"B45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3324\/haematol.2017.179895","article-title":"The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis","volume":"103","author":"Schneeweiss","year":"2018","journal-title":"Haematologica."},{"key":"B46","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"B47","article-title":"Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT","author":"Valent","year":""},{"key":"B48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000048185","article-title":"Smouldering Mastocytosis: A Novel Subtype of Systemic Mastocytosis with Slow Progression","volume":"127","author":"Valent","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00443\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T08:28:21Z","timestamp":1586852901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00443\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":51,"alternative-id":["10.3389\/fphar.2020.00443"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00443","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]},"article-number":"443"}}